Drug intelligence / Profile preview

CGB-S-100

Development stage: Unknown
Lead developer: CAGE Bio
Modality: Small Molecules
Administration: Topical

Overview

**CGB-S-100** is CAGE Bio's topical long-lasting skin-sanitizing gel, marketed as **IonLAST**. It is a fixed topical formulation containing ethanol and choline geranate, a biocompatible choline-geranate ionic liquid also called CAGE or CG-101. Ethanol provides rapid antimicrobial activity after application, while the nonvolatile choline geranate component remains on the skin and is intended to provide residual antimicrobial protection, including against *Staphylococcus aureus* skin colonization. CAGE has demonstrated antibacterial and antibiofilm activity associated with disruption of bacterial membrane homeostasis. ([medrxiv.org](https://www.medrxiv.org/content/10.1101/2020.08.04.20161067v1))

Brand names: IonLAST
Other names: IonLAST gel

Beyond the preview

Go deeper on CGB-S-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CGB-S-100.

Explore the full profile